Equillium to Host Virtual Investor and Analyst Day on December 4, 2020
November 30 2020 - 8:00AM
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company developing itolizumab to treat severe autoimmune and
inflammatory disorders, today announced that it will host a virtual
Investor and Analyst Day on December 4, 2020, from 9:30 a.m. to
12:00 p.m. ET. The event will include a review of the company’s
lead clinical drug candidate, itolizumab, a first-in-class
monoclonal antibody, which is being investigated in ongoing trials
in acute graft-versus-host disease (aGVHD), lupus / lupus nephritis
and uncontrolled asthma.
Presenters include:
• |
John Koreth, M.D., D.Phil. of Dana-Farber Cancer Institute |
|
○ |
Providing a physician’s perspective on itolizumab in GVHD |
• |
Bruce Steel, Chief Executive Officer |
• |
Steve Connelly, Ph.D., Chief Scientific Officer |
• |
Krishna Polu, M.D., Chief Medical Officer |
• |
Joel Rothman, SVP Development Operations |
• |
Jason Keyes, Chief Financial Officer |
The presentations will be followed by Q&A with
management and Dr. Koreth.
A live webcast of the event will be available for
30 days on the Events & Presentations page of the Investor
Relations section of the Company’s website at
https://ir.equilliumbio.com/events-and-presentations.
About ItolizumabItolizumab is a
clinical-stage, first-in-class monoclonal antibody that selectively
targets the CD6-ALCAM pathway. This pathway plays a central role in
modulating the activity and trafficking of T cells that drive a
number of immuno-inflammatory diseases. Equillium acquired rights
to itolizumab through an exclusive partnership with Biocon
Limited.
About EquilliumEquillium is a
clinical-stage biotechnology company leveraging deep understanding
of immunobiology to develop novel products to treat severe
autoimmune and inflammatory disorders with high unmet medical need.
Equillium is developing itolizumab for multiple severe
immuno-inflammatory diseases, including aGVHD, lupus / lupus
nephritis and uncontrolled asthma.
For more information, visit
www.equilliumbio.com.
Forward Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding the potential benefit of treating patients
with aGVHD, lupus / lupus nephritis or uncontrolled asthma with
itolizumab, Equillium’s business strategy, Equillium’s plans and
expected timing for developing itolizumab, including the expected
timing of initiating, completing and announcing further results
from the EQUATE, EQUIP and EQUALISE studies, the potential benefits
of itolizumab, the potential for any of Equillium’s ongoing or
planned clinical trials to show safety or efficacy, and the impact
of the COVID-19 pandemic. Risks that contribute to the uncertain
nature of the forward-looking statements include: the risk that
interim results of a clinical trial do not necessarily predict
final results and that one or more of the clinical outcomes may
materially change as patient enrollment continues, following more
comprehensive reviews of the data, and as more patient data become
available; potential delays in the commencement, enrollment and
completion of clinical trials and the reporting of data therefrom;
the risk that studies will not be completed as planned;
uncertainties related to Equillium’s capital requirements;
Equillium’s plans and product development, including the
initiation, restarting and completion of clinical trials;
uncertainties related to the actual impacts and length of such
impacts caused by the COVID-19 pandemic; uncertainties caused by
the recent restarting of the EQUIP and EQUALISE clinical trials
after a pause; whether the results from clinical trials will
validate and support the safety and efficacy of itolizumab; changes
in the competitive landscape, and uncertainties having to use cash
in ways or on timing other than expected and the impact of market
volatility on cash reserves. These and other risks and
uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Equillium undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
Investor ContactMichael Moore,
Vice President, Investor Relations & Corporate
Communications+1-619-302-4431ir@equilliumbio.com
Media ContactKatherine Carlyle
SmithSenior Account AssociateCanale Communications+1-805-907-2497
katherine.smith@canalecomm.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Sep 2023 to Sep 2024